Table 3 Clinicopathological and genetic data of differentiated thyroid cancers classified by classes based on gene expression
C1QL1 fold change | LCN2 fold change | CRABP1 fold change | CILP fold change | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal ≤ 1 | Gain > 1 | P value | Normal ≤ 1 | Gain > 1 | P value | Loss < −1 | Normal ≥ −1 | P value | Loss < −1 | Normal ≥ −1 | P value | |
DTC (n = 98) | ||||||||||||
Age (n) | 33 | 56 | NS (0.318) | 31 | 55 | NS (0.614) | 75 | 14 | NS (0.826) | 54 | 34 | NS (0.474) |
Mean (years) | 40.9 ± 2.4 | 44.2 ± 2.4 | 42.0 ± 2.2 | 44.0 ± 2.4 | 43.4 ± 1.9 | 41.64 ± 3.7 | 42.9 ± 2.3 | 44.0 ± 2.7 | ||||
Tumour size (n) | 31 | 54 | NS (0.063) | 29 | 53 | NS (0.680) | 71 | 14 | NS (0.220) | 51 | 33 | NS (0.582) |
Mean (cm) | 2.20 ± 0.22 | 3.10 ± 0.27 | 2.59 ± 0.32 | 2.67 ± 0.24 | 2.86 ± 0.22 | 2.29 ± 0.43 | 2.87 ± 0.28 | 2.49 ± 0.23 | ||||
Gender (n) | 33 | 56 | NS (0.148) | 31 | 55 | NS (0.232) | 75 | 14 | NS (0.350) | 54 | 34 | NS (0.175) |
Female (%) | 26 (78.8) | 50 (89.3) | 28 (90.3) | 45 (81.8) | 63 (84.0) | 13 (92.9) | 44 (81.5) | 31 (91.2) | ||||
Male (%) | 7 (21.2) | 6 (10.7) | 3 (9.7) | 10 (18.2) | 12 (16.0) | 1 (7.1) | 10 (18.5) | 3 (8.8) | ||||
Capsule (n) | 30 | 50 | NS (0.263) | 26 | 51 | NS (0.099) | 66 | 14 | 0.037 | 49 | 30 | NS (0.128) |
Positive (%) | 18 (60.0) | 25 (50.0) | 17 (65.4) | 24 (47.1) | 39 (59.1) | 4 (28.6) | 29 (59.2) | 13 (43.3) | ||||
Capsular invasion (n) | 17 | 23 | NS (0.496) | 15 | 23 | NS (0.332) | 37 | 3 | NS (0.704) | 28 | 11 | NS (0.191) |
Positive (%) | 12 (70.6) | 15 (65.2) | 11 (73.3) | 14 (60.9) | 25 (67.6) | 2 (66.7) | 17 (60.7) | 9 (81.8) | ||||
Vascular invasion (n) | 30 | 51 | NS (0.516) | 28 | 51 | NS (0.245) | 67 | 14 | NS (0.060) | 50 | 30 | NS (0.261) |
Positive (%) | 17 (56.7) | 30 (58.8) | 14 (50.0) | 31 (60.8) | 42 (62.7) | 5 (35.7) | 30 (60.0) | 15 (50.0) | ||||
Lymph node metastasis (n) | 31 | 54 | NS (0.398) | 30 | 53 | NS (0.073) | 71 | 14 | NS (0.397) | 51 | 33 | NS (0.074) |
Positive (%) | 7 (22.6) | 15 (27.8) | 5 (16.7) | 18 (34.0) | 21 (29.6) | 3 (21.4) | 10 (19.6) | 12 (36.4) | ||||
Extrathyroidal extension (n) | 30 | 51 | 0.003 | 29 | 50 | 0.020 | 67 | 13 | NS (0.328) | 48 | 32 | NS (0.332) |
Positive (%) | 4 (13.3) | 23 (45.1) | 5 (17.2) | 21 (42.0) | 23 (34.3) | 3 (23.1) | 17 (35.4) | 9 (28.1) | ||||
Distant metastasis (n) | 31 | 54 | NS (0.096) | 30 | 53 | NS (0.401) | 71 | 14 | NS (0.397) | 51 | 33 | NS (0.657) |
Positive (%) | – | 5 (9.3) | 1 (3.33) | 4 (7.55) | 5 (7.04)) | – | 2 (3.92) | 2 (6.06) | ||||
Lymphocytic thyroiditis (n) | 32 | 51 | 0.003 | 30 | 51 | NS (0.416) | 69 | 14 | NS (0.563) | 49 | 33 | NS (0.354) |
Positive (%) | 7 (21.9) | 28 (54.9) | 12 (40.0) | 23 (45.1) | 31 (44.9) | 6 (42.9) | 19 (38.8) | 15 (45.5) | ||||
Oncocytic (n) | 31 | 50 | NS (0.290) | 28 | 51 | 0.018 | 67 | 14 | NS (0.329) | 48 | 32 | NS (0.473) |
Positive (%) | 5 (16.1) | 12 (24.0) | 2 (7.14) | 15 (29.4) | 13 (19.4) | 4 (28.6) | 9 (18.8) | 7 (21.9) | ||||
PAX8-PPARG rearrangements (n) | 33 | 56 | NS (0.371) | 31 | 55 | NS (0.360) | 75 | 14 | NS (0.843) | 54 | 34 | NS (0.386) |
Positive (%) | 1 (3.03) | – | 1 (3.23) | – | 1 (1.33) | – | – | 1 (2.94) | ||||
RET/PTC rearrangements (n) | 33 | 56 | NS (0.493) | 31 | 55 | NS (0.174) | 75 | 14 | NS (0.617) | 54 | 34 | NS (0.160) |
Positive (%) | 5 (15.1) | 10 (17.9) | 3 (9.68) | 11 (20.0) | 12 (16.0) | 2 (14.3) | 7 (13.0) | 8 (23.5) | ||||
RET/PTC1 rearrangement (n) | 33 | 56 | NS (0.618) | 31 | 55 | NS (0.163) | 75 | 14 | NS (0.425) | 54 | 34 | NS (0.070) |
Positive (%) | 4 (12.1) | 7 (12.5) | 2 (6.45) | 9 (16.4) | 10 (13.3) | 1 (7.14) | 4 (7.41) | 7 (20.6) | ||||
RET/PTC3 rearrangement (n) | 33 | 56 | NS (0.629) | 31 | 55 | 1 | 75 | 14 | 1 | 54 | 34 | NS (0.614) |
Positive (%) | – | 1 (1.79) | – | – | – | – | 1 (1.85) | – | ||||
BRAF mutation (n) | 33 | 56 | <0.001 | 31 | 55 | 0.031 | 75 | 14 | 0.025 | 54 | 34 | NS (0.331) |
Positive (%) | – | 18 (32.1) | 3 (9.68) | 16 (29.1) | 19 (25.3) | – | 13 (24.1) | 6 (17.6) | ||||
NRAS mutation (n) | 33 | 56 | NS (0.213) | 31 | 55 | NS (0.300) | 75 | 14 | NS (0.090) | 54 | 34 | 0.001 |
Positive (%) | 7 (21.2) | 7 (12.5) | 6 (19.4) | 7 (12.7) | 13 (17.3) | – | 14 (25.9) | – | ||||
TERT promoter mutation (n) | 33 | 56 | NS (0.244) | 31 | 55 | NS (0.706) | 75 | 14 | NS (0.595) | 54 | 34 | NS (0.669) |
Positive (%) | – | 3 (5.36) | 1 (3.23) | 2 (3.64) | 3 (4.00) | – | 2 (3.70) | 1 (2.94) | ||||